Dexmedetomidine in oxycodone patient-controlled analgesia after lumbar spinal fusion: A randomized, double-blind, placebo-controlled trial
Adding dexmedetomidine to oxycodone PCA provided modest early opioid-sparing effects without reducing 72-h opioid consumption. The main benefit was improved 24-h tolerability, with fewer opioid-related side effects. Dexmedetomidine may therefore serve as a useful adjunct in patients at risk of opioid-induced adverse events after lumbar fusion surgery.
Authors
- Juho Rantakokko (ORCID: https://orcid.org/0000-0002-2678-3168)
- Marko Peltoniemi (ORCID: https://orcid.org/0000-0003-1149-6825)
- Eliisa Löyttyniemi (ORCID: https://orcid.org/0000-0002-7278-6511)
- Janne Gröhn (ORCID: https://orcid.org/0000-0002-0043-8526)
- Panu Uusalo (ORCID: https://orcid.org/0000-0001-5120-8854)
- Antti Liukas
- Sanna M. Mäkelä (ORCID: https://orcid.org/0000-0003-4116-5007)
- Teijo I. Saari (ORCID: https://orcid.org/0000-0003-1225-4561)
- Riku Aantaa
Institutions
- University of Turku (FI)
- Turku University Hospital (FI)
Publication Details
- Journal
- Journal of Clinical Anesthesia
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1016/j.jclinane.2026.112191
- Primary Topic
- Pain Management and Opioid Use
- Type
- article
- Field-Weighted Citation Impact
- 0.00